

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rothe et al.

Serial No. Not yet assigned

Filed: Herewith

For: *Inhibitors of Apoptosis*

Group Art Unit: 1632

Examiner: Woitach, J.

Attorney Docket No. T95-005-2

Date: October 12, 2000

#2  
Da  
2/15/01  
JCS21 U.S. PTO  
09/689366  
10/12/00

This application claims priority to USSN  
08/569,749, filed 12/08/95

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97 (b)

The Commissioner for Patents  
Washington D.C. 20231

Dear Commissioner,

In accordance with 37 C.F.R. §1.56, this Information Disclosure Statement is being submitted for the above-referenced application.

Applicants request the Office to consider this Information Disclosure Statement under 37 C.F.R. §1.97 (b). Accordingly no fees are due for consideration of the items listed on the attached 1449 form.


Applicants presume the Examiner is aware of and has copies of the references cited on the attached, as they were all cited in the parent applications 08/569,749 and 08/512,946. If the Examiner would like copies of any of these references, Applicants will be pleased to provide them.

In accordance with 37 C.F.R. §1.97 (g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined by 37 C.F.R. §1.56 exists.

In accordance with 37 C.F.R. §1.97 (h) the disclosure contained herein is not intended to constitute an admission that any patent, publication, or other information referred to is "prior art" or "analogous art" for this invention.

The Commissioner is hereby authorized to charge any fees, if necessary, or credit any overpayments to Deposit Account No. 19-0750. (Order No. T95-005-2)

Respectfully submitted,  
SCIENCE & TECHNOLOGY LAW GROUP

  
Richard Aron Osman, Ph.D., #36,627  
Tel: (650)343-4341; Fax: (650) 343-4342